NTLA: Intellia Quarterly Revenue Growth

Graphic logo of Intellia Corp (NTLA)

The absence of its own commercial products makes Intellia Therapeutics (NTLA) dependent on external investments and partner payments. However, its status as a leader in genome editing and its patent protection create a powerful barrier for competitors. The quarterly revenue growth rate confirms this trend, where the value -48.40 denotes the current figure. Growth is driven by successful in vivo clinical trials and FDA regulatory approval.

NTLA Intellia Therapeutics Inc Quarterly Revenue Increase (07/04/2022 - 11/20/2026)

Comprehensive metric breakdowns and analytics for Intellia Therapeutics, Inc. (NTLA)

- stock price and consensus target price:
- cash and cash movement details:
Basic company analysis:Intellia Corp - NTLA
Mass-produced product of intelliatx.com

For Intellia Therapeutics (NTLA), whose market capitalization depends on the progress of CRISPR therapy and the commercialization of gene medicines, revenue dynamics reflect the pace of intellectual property monetization. The smoothed percentage growth of quarterly revenue measures sales momentum over three months, allowing investors to differentiate an expansion phase from stagnation and evaluate the efficiency of the operating model through the analysis of this chart.

Competitors of Intellia Therapeutics (NTLA)

TEM - Revenue Growth QoQ|Quarterly Sales Growth Rate qiagen.com QGEN|IONS: Quarterly Revenue Growth|Repligen Corp - Quarterly Revenue Increase|RNA (Avidity Corp) - Quarterly Revenue Growth|CRISPR Therapeutics Corp - Revenue Dynamics QoQ|Revenue Growth QoQ genedx.com (WGS)|Quarterly Revenue Growth ultragenyx.com (RARE)|Quarterly Revenue Growth BEAM (Beam Therapeutics Inc)|Sarepta Therapeutics Inc (SRPT) - Quarterly Revenue Growth Rate|twistbioscience.com - Quarterly Revenue Growth|10x Genomics, Inc. - Sales Change QoQ|STOK: Quarterly Revenue Growth|BLFS - Quarterly Sales Growth Rate|Quarterly Sales Growth WVE|MAZE: Quarterly Revenue Increase|Revenue Growth QoQ Sionna Corp (SION)|Quarterly Sales Growth Rate Prime Medicine Bio|Quarterly Revenue Growth TSHA (Taysha Gene Therapies Inc)|Quarterly Revenue Growth uniqure.com QURE|MeiraGTx Holdings - Quarterly Revenue Growth|RGNX - Quarterly Revenue Growth|SLDB (Solid Corp) - Quarterly Sales Growth|Revenue Change vs Previous Quarter Ocugen Corp OCGN|PACB (Pacific Biosciences) - Quarterly Revenue Growth|Revenue Growth QoQ BNTC|Quarterly Revenue Growth DSGN|Quarterly Sales Growth Rocket Pharma RCKT|Quarterly Sales Growth Rate FDMT|Quarterly Revenue Growth Lexeo Therapeutics LXEO|KRRO - Revenue Growth QoQ|EDIT (Editas Medicine, Inc.) - Sales Growth QoQ|SLN: Quarterly Revenue Growth|ProQR - Quarterly Revenue Increase|CDXS (Codexis) - Quarterly Revenue Growth|Sangamo (SGMO) - Quarterly Sales Growth Rate|Quarterly Revenue Growth NAUT|Quarterly Sales Growth Metagenomi, Inc. MGX|Revenue Growth QoQ Precision BioSciences DTIL|Quarterly Revenue Increase GBIO|BOLD - Revenue Growth QoQ|Quarterly Sales Growth Rate Exicure Inc. XCUR|Imunon, Inc. (IMNN) - Revenue Growth QoQ|RXi Pharmaceuticals - Quarterly Revenue Increase|MBIO (Mustang Bio) - Quarterly Revenue Growth|Sales Growth QoQ RNAZ (transcodetherapeutics.com)|Revenue Growth QoQ Bionano (BNGO)|Applied DNA Sciences - Sales Growth QoQ|Quarterly Revenue Growth BLUE (bluebirdbio.com)|ImmunoPrecise Antibodies (IPA) - Quarterly Revenue Growth Rate|omegatherapeutics.com - Quarterly Revenue Growth|Revenue Change vs Previous Quarter Singular Genomics Systems Inc (OMIC)|RGLS: Quarterly Revenue Growth|Syros Pharmaceuticals, Inc (SYRS) - Quarterly Revenue Growth|TBIO (telesisbio.com) - Quarterly Revenue Growth|TCON: Quarterly Revenue Increase|Revenue Growth QoQ Unity Biotechnology, Inc (UBX)